GÉTICA 2021

57 [ F I T C á n c e r - 7 ] Figure 4. In vivo anti-tumor efficacy of STAb-T19 cells. (a-g) Cell line-derived xenograft murine model: NSG mice (n = 6/group) received 1 × 106 NALM6Luc cells (iv) followed 2 days after by a single iv injection of 5 × 106 NT-T, CAR-T19 (5 × 105 19-BBζ+) or STAb-T19 (5 × 105 19-BiTE+) cells. Tumor progression was monitored weekly by bioluminescence imaging, PB was obtained at days 19 and 39 (sacrifice), and tissue samples were obtained after sacrifice. (a) Timeline of experimental design. (b) Biolumines- cence images showing disease progression. (c) Total radiance quantification at the indicated time points. (d) Change in body weight over time. (e) Detection by FACS of B-ALL cells (CD19+) cells in PB (at day 19) and in spleen and BM (at sacrifice). (f) Relative mRNA expression of CD19 in bone marrow at sacrifice. (g) T cell persistence in PB at days 19 and 39, and in spleen and BM at euthanization. Data are shown as mean ± SD.